Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma

Leukemia Research

Volumn 35, Issue 4, 2011, Pages 431-437

  Rivero, Ana ^a   Rapado, Inmaculada ^a   Tomás, José F ^b   Montalbán, Carlos ^c   de Oña, Raquel ^b   Paz Carreira, José ^d   Canales, Miguel ^e   Martínez, Rafael ^f   Sánchez Godoy, Pedro ^g   de Sevilla, Alberto Fernández ^h   de la Serna, Javier ^a   Martínez López, Joaquín ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b MD ANDERSON CANCER CENTER   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Centro Oncológico Galicia   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL SEVERO OCHOA   (Spain)

^h HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

DCK genotypic variants; Fludarabine; Follicular lymphoma; Toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DEOXYCYTIDINE KINASE; FLUDARABINE; MESSENGER RNA; RITUXIMAB;

ACUTE LEUKEMIA; ANEMIA; APLASTIC ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEURITIS; NEUTROPENIA; PRIORITY JOURNAL; PROMOTER REGION; RESPIRATORY TRACT DISEASE; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEOXYCYTIDINE KINASE; DNA MUTATIONAL ANALYSIS; DRUG TOXICITY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; GENE FREQUENCY; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LYMPHOMA, FOLLICULAR; LYMPHOPENIA; NEUTROPENIA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIDARABINE;

EID: 79952364650     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.09.026     Document Type: Article

References (38)

1. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
2. Van den Neste E., Cardoen S., Offner F., Bontemps F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). Int J Oncol 2005, 27:1113-1124.
3. Song J.J., Walker S., Chen E., Johnson E.E., Spychala J., Gribbin T., et al. Genomic structure and chromosomal localization of the human deoxycytidine kinase gene. Proc Natl Acad Sci U S A 1993, 90:431-434.
4. Ge Y., Jensen T.L., Matherly L.H., Taub J.W. Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity. J Biol Chem 2003, 278:49901-49910.
5. Chen E.H., Johnson E.E., Vetter S.M., Mitchell B.S. Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines. J Clin Invest 1995, 95:1660-1668.
6. Galmarini C.M., Clarke M.L., Jordheim L., Santos C.L., Cros E., Mackey J.R., et al. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 2004, 4:8.
7. Owens J.K., Shewach D.S., Ullman B., Mitchell B.S. Resistance to 1-beta-d-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 1992, 52:2389-2393.
8. Veuger M.J., Honders M.W., Landegent J.E., Willemze R., Barge R.M. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood 2000, 96:1517-1524.
9. Kocabas N.A., Aksoy P., Pelleymounter L.L., Moon I., Ryu J.S., Gilbert J.A., et al. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos 2008, 36:1951-1959.
10. Gamberale R., Galmarini C.M., Fernandez-Calotti P., Jordheim L., Sanchez-Avalos J., Dumontet C., et al. In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine. Biochem Pharmacol 2003, 66:2185-2191.
11. Sacchi S., Pozzi S., Marcheselli R., Federico M., Tucci A., Merli F., et al. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer 2007, 110:121-128.
12. Zinzani P.L., Pulsoni A., Perrotti A., Soverini S., Zaja F., De Renzo A., et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004, 22:2654-2661.
13. Tam C.S., Wolf M.M., Januszewicz E.H., Prince H.M., Westerman D., Seymour J.F. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer 2004, 100:2181-2189.
14. Forstpointner R., Unterhalt M., Dreyling M., Bock H.P., Repp R., Wandt H., et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003-4008.
15. Flinn I.W., Neuberg D.S., Grever M.R., Gordon W.D., Bennett J.M., Paietta E.M., et al. Phase III Trial of Fludarabine Plus Cyclophosphamide compared with Fludarabine for patients with previously untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997. J Clin Oncol 2007, 25.
16. Foon K.A., Boyiadzis M., Land S.R., Marks S., Raptis A., Pietragallo L., et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:498-503.
17. Lamanna N., Jurcic J.G., Noy A., Maslak P., Gencarelli A.N., Panageas K.S., et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009, 27:491-497.
18. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO Classification of Tumours. IARC WHO Classification of Tumours, vol. 3.
19. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
20. Poland Melt Program. http://www.biophys.uni-duesseldorf.de/local/POLAND/poland.html.
21. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
22. Schneider S., Roessli D., Excoffier L. Arlequin: A software for population genetics data analysis Ver 2.000 2002, Genetics and Biometry Lab, Dept of Anthropology, University of Geneva.
23. Shi J.Y., Shi Z.Z., Zhang S.J., Zhu Y.M., Gu B.W., Li G., et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 2004, 14:759-768.
24. Mitchell B.S., Song J.J., Johnson E.E., Chen E., Dayton J.S. Regulation of human deoxycytidine kinase expression. Adv Enzyme Regul 1993, 33:61-68.
25. Kroep J.R., Loves W.J., van der Wilt C.L., Alvarez E., Talianidis I., Boven E., et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002, 1:371-376.
26. Lotfi K., Karlsson K., Fyrberg A., Juliusson G., Jonsson V., Peterson C., et al. The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia. Biochem Pharmacol 2006, 71:882-890.
27. Smal C., Vertommen D., Bertrand L., Ntamashimikiro S., Rider M.H., Van Den Neste E., et al. Identification of in vivo phosphorylation sites on human deoxycytidine kinase. Role of Ser-74 in the control of enzyme activity. J Biol Chem 2006, 281:4887-4893.
28. Lamba J.K., Crews K., Pounds S., Schuetz E.G., Gresham J., Gandhi V., et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 2007, 323:935-945.
29. Al-Madhoun A.S., van der Wilt C.L., Loves W.J., Padron J.M., Eriksson S., Talianidis I., et al. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2′-2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000. Biochem Pharmacol 2004, 68:601-609.
30. Rapado I., Grande S., Albizua E., Ayala R., Hernandez J.A., Gallardo M., et al. High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. J Mol Diagn 2009, 11:155-161.
31. Wu S.B., Wirthensohn M.G., Hunt P., Gibson J.P., Sedgley M. High resolution melting analysis of almond SNPs derived from ESTs. Theor Appl Genet 2008.
32. Joerger M., Bosch T.M., Doodeman V.D., Beijnen J.H., Smits P.H., Schellens J.H. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur J Clin Pharmacol 2006, 62:681-684.
33. Jordheim L.P., Nguyen-Dumont T., Thomas X., Dumontet C., Tavtigian S.V. Differential allelic expression in leucoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3 and TP53. Drug Metab Dispos 2008, 36:2419-2423.
34. Spasokoukotskaja T., Arner E.S., Brosjo O., Gunven P., Juliusson G., Liliemark J., et al. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer 1995, 31A:202-208.
35. Smal C., Van Den Neste E., Maerevoet M., Poire X., Theate I., Bontemps F. Positive regulation of deoxycytidine kinase activity by phosphorylation of Ser-74 in B-cell chronic lymphocytic leukaemia lymphocytes. Cancer Lett 2007, 253:68-73.
36. Antonsson B.E., Avramis V.I., Nyce J., Holcenberg J.S. Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1. Cancer Res 1987, 47:3672-3678.
37. Smal C., Cardoen S., Bertrand L., Delacauw A., Ferrant A., Van den Berghe G., et al. Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells. Biochem Pharmacol 2004, 68:95-103.
38. Busch R., Neese R.A., Awada M., Hayes G.M., Hellerstein M.K. Measurement of cell proliferation by heavy water labeling. Nat Protoc 2007, 2:3045-3057.